US Generic Drug Market Size To Cross USD 721.54 Bn By 2032

The US generic drug market size accounted for US$ 435.54  Bn in 2022 and is projected to reach around USD 721.54 Bn by 2032, growing at a CAGR of 5.18% from 2023 to 2032.

US Generic Drug Market Size 2023 To 2032

Report Summary

The global US generic drug market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the US generic drug market across the globe.

A comprehensive estimate on the US generic drug market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of US generic drug during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@

Report Scope of the US Generic Drug Market

Report CoverageDetails
Market Size in 2022USD 435.54 Billion
Market Size by 2032USD 721.54 Billion
Growth Rate from 2023 to 2032CAGR of 5.18%
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Type, By Route of Administration, By Therapeutic Application, By Distribution Channels

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized US generic drug market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  US Home Healthcare Market Size To Cross USD 278.83 Bn By 2032

Market Players

The report includes the profiles of key US generic drug market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Pfizer Inc
  • Teva Pharmaceuticals USA, Inc
  • Aurobindo Pharma USA, Inc
  • Sun pharma Inc
  • Abbott Laboratories Inc
  • Lupin Pharmaceuticals, Inc
  • Mylan
  • Dr. Reddy’s
  • Novartis
  • Eli Lilly company

Market Segmentation

By Type

  • Pure Generic Drugs
  • Branded Generic Drugs

By Route of Administration

  • Oral
  • Topical
  • Parental
  • others

By Therapeutic Application 

  • Cardiovascular
  • Central nervous system (CNS)
  • Dermatology
  • Oncology
  • Respiratory
  • Others

By Distribution Channels

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.


Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Generic Drug Market 

5.1. COVID-19 Landscape: US Generic Drug Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape List of Suppliers List of Buyers

Chapter 8. Global US Generic Drug Market, By Type

8.1. US Generic Drug Market, by Type, 2022-2032

8.1.1. Pure Generic Drugs Market Revenue and Forecast (2022-2032)

8.1.2. Branded Generic Drugs Market Revenue and Forecast (2022-2032)

Chapter 9. Global US Generic Drug Market, By Route of Administration

9.1. US Generic Drug Market, by Route of Administration, 2022-2032

9.1.1. Oral Market Revenue and Forecast (2022-2032)

9.1.2. Topical Market Revenue and Forecast (2022-2032)

9.1.3. Parental Market Revenue and Forecast (2022-2032)

9.1.4. Others Market Revenue and Forecast (2022-2032)

Chapter 10. Global US Generic Drug Market, By Therapeutic Application 

10.1. US Generic Drug Market, by Therapeutic Application, 2022-2032

10.1.1. Cardiovascular Market Revenue and Forecast (2022-2032)

10.1.2. Central nervous system (CNS) Market Revenue and Forecast (2022-2032)

10.1.3. Dermatology Market Revenue and Forecast (2022-2032)

10.1.4. Oncology Market Revenue and Forecast (2022-2032)

10.1.5. Respiratory Market Revenue and Forecast (2022-2032)

10.1.6. Others Market Revenue and Forecast (2022-2032)

Chapter 11. Global US Generic Drug Market, By Distribution Channels 

11.1. US Generic Drug Market, by Distribution Channels, 2022-2032

11.1.1. Retail Pharmacies Market Revenue and Forecast (2022-2032)

11.1.2. Online Pharmacies Market Revenue and Forecast (2022-2032)

11.1.3. Hospital Pharmacies Market Revenue and Forecast (2022-2032)

11.1.4. Others Market Revenue and Forecast (2022-2032)

Chapter 12. Global US Generic Drug Market, Regional Estimates and Trend Forecast

12.1. U.S.

12.1.1. Market Revenue and Forecast, by Type (2022-2032)

12.1.2. Market Revenue and Forecast, by Route of Administration (2022-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Application (2022-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channels (2022-2032)

Chapter 13. Company Profiles

13.1. Pfizer Inc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceuticals USA, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Aurobindo Pharma USA, Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sun pharma Inc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Abbott Laboratories Inc

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lupin Pharmaceuticals, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Mylan

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Dr. Reddy’s

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Novartis

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Eli Lilly company

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333



Show More

Related Articles

Back to top button